Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wade, Katrina
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer	Recruiting	3	418	Europe, Canada, Japan, US, RoW	Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab	AbbVie, GOG Foundation	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	03/27	04/29
Chrzan, Rachael
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer	Recruiting	3	418	Europe, Canada, Japan, US, RoW	Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab	AbbVie, GOG Foundation	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	03/27	04/29

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wade, Katrina
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer	Recruiting	3	418	Europe, Canada, Japan, US, RoW	Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab	AbbVie, GOG Foundation	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	03/27	04/29
Chrzan, Rachael
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer	Recruiting	3	418	Europe, Canada, Japan, US, RoW	Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab	AbbVie, GOG Foundation	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	03/27	04/29